Dawood Shehzad, Helean S Barwari, Mustafa Shehzad, Garcia Alfredo
{"title":"替莫唑胺治疗多形性胶质母细胞瘤后巨细胞病毒脑室炎","authors":"Dawood Shehzad, Helean S Barwari, Mustafa Shehzad, Garcia Alfredo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report a case of a male in his 60s with a past medical history of glioblastoma status post chemoradiotherapy and surgical resection. He had completed neoadjuvant temozolomide and was 26 days post-chemotherapy on presentation. He presented with fever, weakness, and confusion. Further evaluation revealed cytomegalovirus (CMV) ventriculoencephaltis. He was started on valganciclovir, but his hospital course was complicated by a pulmonary embolism. Repeat imaging showed tumor progression, and he was a poor surgical candidate. This case highlights the complexities of managing patients with opportunistic infections post-chemotherapy. It adds to the growing literature of disseminated, invasive, and often lethal CMV infections in non-HIV patients post-use of temozolomide. We urge the need for vigilant monitoring and consideration of prophylactic measures in individuals deemed at risk for invasive CMV.</p>","PeriodicalId":39219,"journal":{"name":"South Dakota medicine : the journal of the South Dakota State Medical Association","volume":"78 2","pages":"77-82"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cytomegalovirus Ventriculoencephaltis Post-Temozolomide Use For Glioblastoma Multiforme.\",\"authors\":\"Dawood Shehzad, Helean S Barwari, Mustafa Shehzad, Garcia Alfredo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We report a case of a male in his 60s with a past medical history of glioblastoma status post chemoradiotherapy and surgical resection. He had completed neoadjuvant temozolomide and was 26 days post-chemotherapy on presentation. He presented with fever, weakness, and confusion. Further evaluation revealed cytomegalovirus (CMV) ventriculoencephaltis. He was started on valganciclovir, but his hospital course was complicated by a pulmonary embolism. Repeat imaging showed tumor progression, and he was a poor surgical candidate. This case highlights the complexities of managing patients with opportunistic infections post-chemotherapy. It adds to the growing literature of disseminated, invasive, and often lethal CMV infections in non-HIV patients post-use of temozolomide. We urge the need for vigilant monitoring and consideration of prophylactic measures in individuals deemed at risk for invasive CMV.</p>\",\"PeriodicalId\":39219,\"journal\":{\"name\":\"South Dakota medicine : the journal of the South Dakota State Medical Association\",\"volume\":\"78 2\",\"pages\":\"77-82\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"South Dakota medicine : the journal of the South Dakota State Medical Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Dakota medicine : the journal of the South Dakota State Medical Association","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Cytomegalovirus Ventriculoencephaltis Post-Temozolomide Use For Glioblastoma Multiforme.
We report a case of a male in his 60s with a past medical history of glioblastoma status post chemoradiotherapy and surgical resection. He had completed neoadjuvant temozolomide and was 26 days post-chemotherapy on presentation. He presented with fever, weakness, and confusion. Further evaluation revealed cytomegalovirus (CMV) ventriculoencephaltis. He was started on valganciclovir, but his hospital course was complicated by a pulmonary embolism. Repeat imaging showed tumor progression, and he was a poor surgical candidate. This case highlights the complexities of managing patients with opportunistic infections post-chemotherapy. It adds to the growing literature of disseminated, invasive, and often lethal CMV infections in non-HIV patients post-use of temozolomide. We urge the need for vigilant monitoring and consideration of prophylactic measures in individuals deemed at risk for invasive CMV.